A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.

Yee Chao,Thomas Yau,Marina Maglakelidze,Iurie Bulat,Suebpong Tanasanvimon,Chaiyut Charoentum,Wichit Arpornwirat,Jedzada Maneechavakajorn,Arunee Dechaphunkul,Teerapat Ungtrakul,Chia-Jui Yen,Li Yuan Bai,Wen-Chi Chou,Ursula Wiedermann,Anthony J. Good,Nick Ede,Leslie Chong

A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.

2019

Yee Chao
Thomas Yau
Marina Maglakelidze
Iurie Bulat
Suebpong Tanasanvimon
Chaiyut Charoentum
Wichit Arpornwirat
Jedzada Maneechavakajorn
Arunee Dechaphunkul
Teerapat Ungtrakul
Chia-Jui Yen
Li Yuan Bai
Wen-Chi Chou
Ursula Wiedermann
Anthony J. Good
Nick Ede
Leslie Chong

4030Background: Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer deaths. HER2/neu is overexpressed in 15% - 25% of patients with gastric cancer. Monoclonal antibodie...

Keywords:

Gastroesophageal Junction
Peptide vaccine
Stomach
Cancer research
Pathology
HER2/neu
Medicine
Chemotherapy
Adenocarcinoma
in patient
Cancer
Monoclonal

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations